Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2011

Abbott Pays Biotest $85M Up Front in Deal for Phase II mAb Against RA and Psoriasis

  • Abbott Laboratories and Biotest entered a global agreement to develop and commercialize BT-061, an anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. Biotest will receive an up-front fee of $85 million and up to $395 million linked to the achievement of development, regulatory, commercial, and sales-based milestones.

    BT-061 is currently in Phase II trials for both indications, and preclinical studies are under way to study its potential in other immune-related diseases. It works by activating the body's T-regulatory cells, strengthening a natural function of the body that prevents excessive immune reactions. Unlike other anti-CD4 antibodies that have been in development, BT-061 does not cause depletion of CD4 positive T-cells that would give rise to weakened immune responses, according to Biotest.

    Under terms of the agreement, Biotest will be responsible for manufacturing the initial clinical supply of BT-061, and the companies will share responsibility for commercial production. The firms will co-promote BT-061 in five major European markets (Germany, France, U.K., Italy, and Spain). Abbott will have exclusive global rights to commercialize BT-061 outside those countries.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »